Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | July 13, 2020 | July 13, 2020 |
| ArriVent BioPharma, Inc.AVBP · Entity 4699 | Director | June 18, 2026 | June 23, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Medical Officer | December 10, 2024 | December 12, 2024 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,746 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 83,746 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Arcus Biosciences, Inc.
Report date July 13, 2020 · Filed July 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2020-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
ArriVent BioPharma, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.74 · Expires 2036-06-17 | Direct | 13,562 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 13,562 · Balance 13,562 F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
GILEAD SCIENCES, INC.
Report date December 10, 2024 · Filed December 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,850 |
Ending reported balance
After 2024-12-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-12-10 · Exercise / conversion · Acquired 3,820 · Balance 84,621 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2024-12-10 · Tax withholding · Disposed 1,771 · Balance 82,850 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,753 |
Reported balance
After 2024-12-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-10 · Exercise / conversion · Disposed 3,820 · Balance 36,753 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Sagimet Biosciences Inc.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2034-06-04 | Direct | 51,459 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 51,459 · Balance 51,459 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 5, 2024, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2023 Filed Dec 12, 2023 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,269 | $79.02 | $100,276.38 |
DisclosureSEC source: 0001127602-23-029247 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,640 Read SEC document |
| December 10, 2023 Filed Dec 12, 2023 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029247 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,501 | $76.99 | $115,561.99 |
DisclosureSEC source: 0001127602-23-024115 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,130 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 30, 2022. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,754 Underlying: Common Stock · 2,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,278 | $76.00 | $97,128.00 |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,631 Read SEC document |
| September 10, 2023 Filed Sep 12, 2023 00:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-023979 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 23,839 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 14 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,839 Underlying: Series A Common Stock · 23,839 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,839 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 13 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,839 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 23,216 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 12 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,216 Underlying: Series A Common Stock · 23,216 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,216 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 11 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,216 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 144 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 10 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144 Underlying: Series A Common Stock · 144 shares Expires 2025-02-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 144 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 9 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144 shares Expires 2025-02-05 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 3,349 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 8 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,349 Underlying: Series A Common Stock · 3,349 shares Expires 2024-12-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,349 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 7 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,349 shares Expires 2024-12-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 2,086 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 6 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,086 Underlying: Series A Common Stock · 2,086 shares Expires 2024-03-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,086 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 5 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,086 shares Expires 2024-03-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | ConversionSeries E Preferred Stock · Derivative | 327,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Series A Common Stock · 4,117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · kind: Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Series E Preferred Stock had no expiration date. F1 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F1 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | ConversionSeries A Common Stock | 4,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Series E Preferred Stock had no expiration date. F2 · price: Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Series E Preferred Stock had no expiration date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 8,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,677 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerCommon Stock | 8,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-082729 · tm2321276-18_4seq1.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 21:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,485 | $76.90 | $114,196.50 |
DisclosureSEC source: 0001127602-23-018727 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,402 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 30, 2022. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018588 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,533 Underlying: Common Stock · 2,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,294 | $78.12 | $101,087.28 |
DisclosureSEC source: 0001127602-23-018588 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,887 Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 20:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018588 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 22:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,126 | $78.99 | $483,892.74 |
DisclosureSEC source: 0001127602-23-010126 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,130 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $79.50 | $0.00 |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · derivative · entry 7 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2033-03-10 F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 16,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · derivative · entry 6 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,312 Underlying: Common Stock · 16,665 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 7,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · derivative · entry 5 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,647 Underlying: Common Stock · 7,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · derivative · entry 4 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,646 Underlying: Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,328 | $79.50 | $423,576.00 |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,256 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-009986 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,984 | $79.96 | $1,038,225.31 |
DisclosureSEC source: 0001127602-23-008491 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,130 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $79.60 to $80.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 15, 2023 Filed Feb 23, 2023 21:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 376 | $56.38 | $21,199.07 |
DisclosureSEC source: 0001127602-23-006763 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,114 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 17,749 | $84.02 | $1,491,270.98 |
DisclosureSEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,738 Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 43,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,487 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2020. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 20:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 29,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002286 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,772 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021 and March 10, 2022. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 01:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 553 | $85.33 | $47,187.49 |
DisclosureSEC source: 0001127602-23-000216 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,556 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,101 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 486 | $87.97 | $42,753.42 |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,109 Read SEC document |
| December 10, 2022 Filed Dec 13, 2022 20:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-027389 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 5,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,140 Underlying: Common Stock · 5,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,268 | $82.60 | $187,336.80 |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,556 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 17:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-025411 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,239 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 481 | $65.28 | $31,399.68 |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,725 Read SEC document |
| September 10, 2022 Filed Sep 12, 2022 20:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-022290 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · derivative · entry 3 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,278 Underlying: Common Stock · 1,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 485 | $60.74 | $29,458.90 |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · nonDerivative · entry 2 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017322 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.